GW reports Phase III Sativex MS data

GW Pharmaceuticals (LSE:GWP) said in a double-blind Phase III trial in 189 patients with multiple sclerosis (MS), its Sativex sublingual cannabis extract spray significantly improved spasticity compared to placebo, the primary endpoint (p<0.05). In addition to study medication, all patients remained on their existing medication. ...